Strategic trends in the drug industry

Drug Discovery Today

Volumn 8, Issue 9, 2003, Pages 411-420

  Drews, Jürgen ^a,b  

^a Bear Stearns & Co Inc   (United States)

^b NONE   (Germany)

Author keywords

Biotechnology; Drug discovery; Drug industry; Genomics; Innovation deficit; Strategies

Indexed keywords

IMATINIB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

BIOTECHNOLOGY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; GENOMICS; PRODUCTIVITY; PROFIT; PROTEIN PROTEIN INTERACTION; REVIEW; VALIDATION PROCESS; DRUG DESIGN; ECONOMICS; FORECASTING; HUMAN; MARKETING; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PHARMACEUTICS; RESEARCH;

BIOTECHNOLOGY; DRUG DESIGN; DRUG INDUSTRY; FORECASTING; GENOMICS; HUMANS; MARKETING; ORGANIZATIONAL INNOVATION; RESEARCH; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037404094     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02690-4     Document Type: Review

References (25)

1. Drews J., Ryser S.T. An innovation deficit in the pharmaceutical industry. Drug Inf. J. 30:1996;97-108.
2. Drews, J. (1995) The impact of cost containment on pharmaceutical research and development. Tenth Centre of Medicines Research (CMR) Lecture.
3. Duelli J., van-der-Locht A. Trends in Biotechnology. 2001;Bain and Company.
4. CMR International (2002) R&D Cycle Times Data Base. (available at: http://www.cmr.org ).
5. Tufts Center for the Study of Drug Development (1995-1999) New Biopharmaceuticals in the US.
6. Health, IMS. Growth in new active substances, how biotechnology drugs are making inroads. (available at: http://www.imshealth.com/public/structure/dispcontent/1,2779 ).
7. Datamonitor (2002). The New Generation of Blockbusters, May 2002, pp. 6,26.
8. Drews J. In Quest of Tomorrow's Medicines. 2nd edn:2003;Springer, New York.
9. Blockbusters behind the Productivity Drop. Scrip, World Pharmaceutical News, 18 December 2002, p. 2.
10. Drews J. Quo vadis - Biotechnology? Part I. Drug Discov. Today. 5:2000;547-553.
11. Drews J. Quo vadis - Biotechnology? Part II. Drug Discov. Today. 6:2001;21-26.
12. Luxon B.A., et al. Pegylated Interferons in the treatment of chronic hepatitis. Clin. Ther. 24:2002;1363-1383.
13. Weinstock-Guttman B., Jacobs L.D. What is new in the treatment of multiple sclerosis? Drugs. 3:2000;401-410.
14. Lander E. Beyond the Human Genome Project. Human Disease-from Genetic Cause to Biochemical Effects. 1997;Blackwell Science.
15. including trends in success rates. April. 2002:2002;5,6,12.
16. Drysdale C.M., et al. Complex promoter and coding region β-2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10483-10488.
17. Stephens J.C., et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science. 293:2001;489-493.
18. Borman S., et al. In situ click chemistry. Chem. Eng. News. 80:2002;29-34.
19. Arlington S.T., et al. Pharma 2010: The Threshold of Innovation. 2002;IBM Business Consulting Publication.
20. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1964.
21. Hernandez-Boluda J.C., Cervantes F. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic leukemia and other malignancies. Drugs Today. 38:2002;601-613.
22. Wrighton N.C., et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 273:1996;458-464.
23. Livnah O., et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 273:1996;464-471.
24. Kuhn T.H. The Structure of Scientific Revolution. 2nd edn:1970;University of Chicago, University Press.
25. th Annual Pharmaceutical Conference, London, February 13-14.